CMIE Educational Series FY 2019: Paradigm Change: Cardiovascular and Renal Protection w/Type 2 Diabetes Medications
Starts On:
Fri, 10/26, 2018: 12:00 AM
Ends On:
Mon, 10/26, 2020: 12:00 AM
Type:
Enduring Material
Credits:
0.75
Description:
This lecture will review the current information about cardiovascular and renal protective effects of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. It will review the current CV risk statistics in type 2 diabetes; define the FDA mandate for cardiovascular outcome trials (CVOTs) with new diabetes drugs; describe the clinical characteristics and results of these CVOTs with SGLT2 inhibitors and GLP-1 receptor agonists; describe recent changes in type 2 DM treatment algorithms.
Estimated Time to Complete: 45 minutes
Date of Review: 10/23/18
Termination Date: 7/30/20
ACCREDITATION INFORMATION
In support of improving patient care, The Robert Larner College of Medicine at the University of Vermont is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Vermont designates this Enduring Material activity for a maximum of .75 AMA PRA Category 1 Credits™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been reviewed and is acceptable for up to .75 Nursing Contact Hours.
Estimated Time to Complete: 45 minutes
Date of Review: 10/23/18
Termination Date: 7/30/20
ACCREDITATION INFORMATION
In support of improving patient care, The Robert Larner College of Medicine at the University of Vermont is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Vermont designates this Enduring Material activity for a maximum of .75 AMA PRA Category 1 Credits™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been reviewed and is acceptable for up to .75 Nursing Contact Hours.
Objectives:
1. Describe the standard design features and how to interpret the findings of Cardiovascular Outcome Trials in type 2 diabetes.
2. Discuss the general cardiovascular and renal protective effects of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
2. Discuss the general cardiovascular and renal protective effects of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
Additional Resources:
TEAM-BASED MESSAGE
Coordination of care is essential for type 2 diabetes management.
CONTACT INFORMATION
CMIE Office
UVMCMIE@med.uvm.edu
Coordination of care is essential for type 2 diabetes management.
CONTACT INFORMATION
CMIE Office
UVMCMIE@med.uvm.edu
Disclosure Information:
There are no financial disclosures for CMIE staff or reviewers.
FACULTY DISCLOSURE
John Leahy, MD - Advisory Boards - Novo Nordisk, Merck, Sanofi, Jansson
FACULTY DISCLOSURE
John Leahy, MD - Advisory Boards - Novo Nordisk, Merck, Sanofi, Jansson
Topic Categories:
CMIE Educational Series
